Diagnosis and treatment of kidney disease

Best Practice and Research: Clinical Rheumatology

Volumn 19, Issue 5 SPEC. ISS., 2005, Pages 785-798

  Cross, Jane ^a   Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Classification; Lupus nephritis; Mycophenolate mofetil; Renal biopsy; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CHLORAMBUCIL; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 4 ANTIBODY; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID;

ALOPECIA; AMENORRHEA; BLADDER DISEASE; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DOSE CALCULATION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MECHANISM; DRUG PULSE THERAPY; EARLY DIAGNOSIS; FEMALE; HERPES; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MALE; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; OVARY INSUFFICIENCY; PREDICTION; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REMISSION; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; URINALYSIS; WORLD HEALTH ORGANIZATION;

EID: 24344501720     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2005.05.005     Document Type: Review

References (59)

1. J.J.S. Cameron Clinical manifestations of lupus nephritis In: E.J. Lewis M.M. Schwartz S.M. Korbet (eds) Lupus Nephritis 1999 Oxford University Press Oxford 159-184
2. D.J. Newman H. Thakkar R.G. Edwards et al. Serum cystatin C is a more sensitive marker of changes in GFR than serum creatinine Kidney International 47 1 1995 312-318
3. A. Harmoinen T. Lehtimäki M. Korpela et al. Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft-Gault and Levey (MDRD) formulas Clinical Chemistry 49 2003 1223-1225
4. A.S. Levey J.P. Bosch J.B. Lewis et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group Annals of Internal Medicine 6 1999 461-470
5. E.J. Kingdon C.J. Knight K. Dustan et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment Rheumatology 1 2003 26-33
6. L. Christopher-Stine M. Petri B.C. Astor D. Fine Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis The Journal of Rheumatology 8 2004 1557-1559
7. J.J. Weening V.D. D'Agati M.M. Schwartz et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited Journal of the American Society of Nephrology 15 2004 241-250
8. A.J. Howie H. Turhan D. Adu Powerful morphometric indicator of prognosis in lupus nephritis Quarterly Journal of Medicine 6 2003 411-420
9. G. Moroni S. Pasquali S. Quaglini et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis American Journal of Kidney Diseases 3 1999 530-539
10. J.E. Balow H.A. Austin 3rd Therapy of membranous nephropathy in systemic lupus erythematosus Seminars in Nephrology 4 2003 386-391
11. C.C. Najafi S.M. korbet E.J. Lewis et al. Significance of histologic patterns of glomerular injury upon long term prognosis in severe lupus nephritis Kidney International 6 2001 2156-2163
12. L. Bono J.S. Cameron J.A. Hicks The very long-term prognosis and complications of lupus nephritis and its treatment Quarterly Journal of Medicine 4 1999 211-218
13. S.M. Korbet E.J. Lewis M.M. Schwartz et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group American Journal of Kidney Diseases 5 2000 904-914
14. J.C. Nossent W. Bronsveld A.J. Swaak Systemic lupus erythematosusIII. Observations on clinical renal involvement and follow-up of renal function: Dutch experience with 110 patients studied prospectively Annals of the Rheumatic Diseases 10 1989 810-816
15. J. Cortez-Hernandez J. Ordi-Ros M. Labrador et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone Lupus 12 2003 287-296
16. G. Moroni D. Ventura P. Riva et al. Antiphospholipid antibodies are associated with an increased risk of chronic renal insufficiency in patients with lupus nephritis American Journal of Kidney Diseases 1 2004 28-36
17. R.G. Barr S. Seliger G.B. Appel et al. Prognosis in proliferative lupus nephritis: The role of socio-economic status and race/ethnicity Nephrology Dialysis Transplantation 10 2003 2039-2046
18. J.M. Esdaile C. Levinton W. Federgreen et al. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature Quarterly Journal of Medicine 269 1989 779-833
19. J.M. Esdaile L. Joseph T. MacKenzie et al. The benefit of early treatment with immunosuppressive agents in lupus nephritis The Journal of Rheumatology 11 1994 2046-2051
20. G.G. Illei K. Takada D. Parkin et al. Renal Flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term follow-up of a cohort of 145 patients participating in randomised controlled studies Arthritis and Rheumatism 4 2002 995-1002
21. G. Moroni S. Quaglini M. Maccario et al. Nephritic flares are predictors of bad long-term renal outcome in lupus nephritis Kidney International 6 1996 2047-2053
22. C.C. Mok K.Y. Ying S. Tang et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis Arthritis and Rheumatism 8 2004 2559-2568
23. L. Fraenkel T. MacKenzie L. Joseph et al. Response to treatment as a predictor of long-term outcome in patients with lupus nephritis The Journal of Rheumatology 1994 2052-2057
24. A. Doria C. Vitali A. Tincani et al. International survey on the management of patients with SLE. III. The results of a questionnaire regarding renal involvement Clinical and Experimental Rheumatology 14 supplement 16 1996 S31-S38
25. A.J. Mangrum G.L. Bakris Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: Safety issues Seminars in Nephrology 2 2004 168-175
26. C.C. Mok K.Y. Ying C.S. Lau et al. Treatment of pure membranous lupus nephropathy with prednisolone and azathioprine: An open label trial American Journal of Kidney Diseases 2 2004 269-276
27. D.N. Spetie Y. Tang B.H. Rovin et al. Mycophenolate therapy of SLE membranous nephropathy Kidney International 6 2004 2411-2415
28. G. Moroni M. Maccario G. Banfi et al. Treatment of membranous lupus nephritis American Journal of Kidney Diseases 4 1998 681-686
29. R.S. Flanc M.A. Roberts G.F.M. Strippoli et al. Treatment of diffuse proliferative lupus nephritis: A meta-analysis of randomised controlled trials American Journal of Kidney Diseases 2 2004 197-208
30. C.C. Mok C.T. Ho Y.P. Siu et al. Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide containing regimens American Journal of Kidney Diseases 2 2001 256-264
31. M.c. Park Y.B. Park S.Y. Jung et al. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy Lupus 8 2004 569-574
32. G.E. Katsifis A.G. Tzioufas Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide Lupus 9 2004 673-678
33. A. Valeri J. Radhakrishnan D. Estes et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: A prospective five-year study Clinical Nephrology 2 1994 71-78
34. H.A. Austin J.H. Klippel J.E. Balow et al. Therapy of lupus nephritis The New England Journal of Medicine 314 1986 614-619
35. D.T. Boumpas H.A. Austin E.M. Vaughn et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis Lancet 340 1992 741-745
36. F.A. Houssiau C. Vasconcelos D. D'Cruz et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial Arthritis and Rheumatism 12 2004 3934-3940
37. K. Takada G.G. Illei D.T. Boumpas Cyclophosphamide for the treatment of systemic lupus erythematosus Lupus 10 2001 154-161
38. C.C. Mok K.N. Lai Mycophenolate mofetil in lupus glomerulonephritis American Journal of Kidney Diseases 3 2002 447-457
39. M.T. Chan F.K. Li C.S.O. Tang Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis The New England Journal of Medicine 343 16 2000 1156-1162
40. M.T. Chan W.S. Wong C.S. Lau et al. Prolonged follow-up of patients with diffuse proliferative lupus nephritis treated with prednisolone and mycophenolate mofetil Journal of the American Society of Nephrology 12 2001 1010
41. E.J. Kingdon A.G. McLean E. Psimenou et al. The safety and efficacy of MMF in lupus nephritis: A pilot study Lupus 9 2001 606-611
42. M.Y. Karim P. Alba M.J. Cuadrado et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents Rheumatology 8 2002 876-882
43. L. Li H. Wang S. Lin et al. Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: A multicenter trial in China Zhonghua Nei Ke Za Zhi 7 2002 476-479
44. G. Appel E.M. Ginzler J. Radhakrishnan et al. Multicenter controlled trial of mycophenolate mofetil as induction treatment for severe lupus nephritis Journal of the American Society of Nephrology 14 2003 38A
45. P.P. Kapitsinou J.N. Boltis F.N. Skopouli et al. Lupus nephritis: Treatment with mycophenolate mofetil Rheumatology 3 2004 377-380
46. Cross J, Adu D, Andrews P, et al. et al. Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron 2005; 100: 92-100.
47. A.W. Van den Wall Bake J.H. Berden R.H. Derksen et al. Therapy of proliferative lupus glomerulonephritis: A prospective trial in The Netherlands The Netherlands Journal of Medicine 6 1994 280-284
48. C.S. Yee C. Gordon C. Dostal et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis Annals of the Rheumatic Diseases 5 2004 525-529
49. G. Contreras V. Pardo B. Leclercq et al. Sequential therapies for proliferative lupus nephritis The New England Journal of Medicine 10 2004 971-980
50. F.A. Houssiau Management of lupus nephritis; an Update Journal of the American Society of Nephrology 15 2004 2694-2704
51. F.A. Houssiau Management of lupus nephritis; an Update Chinese Medical Journal 12 2003 1827-1830
52. Hu W, Liu Z, Shen S, Li S, et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin. Med. J. 2002; 115: 705-709
53. L. Ferrario M. Bellone E. Bozzolo et al. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A Rheumatology 2 2000 218-220
54. H. Tanaka T. Nakahata K. Tsugawa et al. Mizoribine pulse therapy for patients with flares of lupus nephritis: A 1-year observation Clinical Nephrology 2 2004 165-166
55. G.P. Fra G.C. Avanzi E. Bartoli Remission of refractory lupus nephritis with a protocol including rituximab Lupus 10 2003 783-787
56. R.J. Looney J.H. Anolik D. Campbell et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab Arthritis and Rheumatism 8 2004 2580-2589
57. W. Stohl S. Metyas S.M. Tan B lymphocyte stimulator over expression in patients with systemic lupus erythematosus: Longitudinal observations Arthritis and Rheumatism 12 2003 3475-3486
58. F.B. Karassa A. Tatsioni J.P. Ionnidis Design, quality and bias in randomised controlled trials of systemic lupus erythematosus The Journal of Rheumatology 5 2003 979-984
59. D.T. Boumpas J.E. Balow Outcome criteria for lupus nephritis trials: A critical overview Lupus 7 1998 622-629